organization · Reporting owner
Celadon Partners SPV 24
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Senti Biosciences Holdings, Inc.SNTI · Entity 7935 | 10% owner | March 10, 2025 | March 14, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Senti Biosciences Holdings, Inc.
Report date March 10, 2025 · Filed March 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,777,000 |
Reported balance
After 2025-03-10 transaction · row 1
1 source rowRow 1 · 2025-03-10 · Conversion · Acquired 9,777,000 · Balance 9,777,000 F1: Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") was convertible into 1,000 shares of Common Stock either (i) automatically, at the Issuer's option or (ii) upon the election of the holder. On March 10, 2025, the Issuer exercised its right to automatically convert each share of Series A Preferred Stock, resulting in the acquisition of 9,777,000 shares of Common Stock. The Series A Preferred Stock had no expiration date. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-03-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-03-10 · Conversion · Disposed 9,777 · Balance 0 F1: Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") was convertible into 1,000 shares of Common Stock either (i) automatically, at the Issuer's option or (ii) upon the election of the holder. On March 10, 2025, the Issuer exercised its right to automatically convert each share of Series A Preferred Stock, resulting in the acquisition of 9,777,000 shares of Common Stock. The Series A Preferred Stock had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") was convertible into 1,000 shares of Common Stock either (i) automatically, at the Issuer's option or (ii) upon the election of the holder. On March 10, 2025, the Issuer exercised its right to automatically convert each share of Series A Preferred Stock, resulting in the acquisition of 9,777,000 shares of Common Stock. The Series A Preferred Stock had no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 10, 2025 Filed Mar 14, 2025 15:52 UTC | Senti Biosciences Holdings, Inc. SNTI · Entity 7935 | ConversionSeries A Convertible Preferred Stock · Derivative | 9,777 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001079973-25-000394 · ownership.xml · derivative · entry 2 Celadon Partners SPV 24 · CIK 0002060465 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,777,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") was convertible into 1,000 shares of Common Stock either (i) automatically, at the Issuer's option or (ii) upon the election of the holder. On March 10, 2025, the Issuer exercised its right to automatically convert each share of Series A Preferred Stock, resulting in the acquisition of 9,777,000 shares of Common Stock. The Series A Preferred Stock had no expiration date. F1 · price: Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") was convertible into 1,000 shares of Common Stock either (i) automatically, at the Issuer's option or (ii) upon the election of the holder. On March 10, 2025, the Issuer exercised its right to automatically convert each share of Series A Preferred Stock, resulting in the acquisition of 9,777,000 shares of Common Stock. The Series A Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") was convertible into 1,000 shares of Common Stock either (i) automatically, at the Issuer's option or (ii) upon the election of the holder. On March 10, 2025, the Issuer exercised its right to automatically convert each share of Series A Preferred Stock, resulting in the acquisition of 9,777,000 shares of Common Stock. The Series A Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") was convertible into 1,000 shares of Common Stock either (i) automatically, at the Issuer's option or (ii) upon the election of the holder. On March 10, 2025, the Issuer exercised its right to automatically convert each share of Series A Preferred Stock, resulting in the acquisition of 9,777,000 shares of Common Stock. The Series A Preferred Stock had no expiration date. Read SEC document |
| March 10, 2025 Filed Mar 14, 2025 15:52 UTC | Senti Biosciences Holdings, Inc. SNTI · Entity 7935 | ConversionCommon Stock | 9,777,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001079973-25-000394 · ownership.xml · nonDerivative · entry 1 Celadon Partners SPV 24 · CIK 0002060465 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,777,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") was convertible into 1,000 shares of Common Stock either (i) automatically, at the Issuer's option or (ii) upon the election of the holder. On March 10, 2025, the Issuer exercised its right to automatically convert each share of Series A Preferred Stock, resulting in the acquisition of 9,777,000 shares of Common Stock. The Series A Preferred Stock had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.